Autolus Therapeutics plc — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Christian Itin (CEO) and Robert Dolski (CFO) executed standard Sarbanes-Oxley 302/906 certifications for the Q2 2026 10-Q (quarter ended June 30, 2026), filed August 11, 2026. The certifications attest to accuracy of financial statements, effectiveness of disclosure controls and internal controls over financial reporting, and absence of fraud. No specific operational, financial, or business changes are detailed in these exhibit pages—they are boilerplate officer attestations.
Why this rating
Routine mandatory SOX certifications. No operational events, deals, financials, or business developments disclosed. Administrative compliance filing.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.